- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
Hyperpigmentation Disorder Treatment Market is expected to reach US$ 11.78 billion by 2030
Feb 16, 2024
Progenics and Curium Announced European Collaboration for Prostate Cancer Imaging Agent PyL
Sep 03, 2019
Innovation Disrupting the Pricing of Drugs in Healthcare Industry
Jan 23, 2020
Physiological Saline Market is expected to reach US$ 9,057.04 million by 2030
Dec 29, 2023
Genentech’s Fenebrutinib Shows Breakthrough MS Results
Feb 16, 2026
North America Intravenous Immunoglobulin Market is expected to reach US$ 8,747.81 million by 2030
Oct 10, 2023
Asia Pacific Pharmaceutical Drug Delivery Market is anticipated to grow during 2019-2027 with a CAGR value of 7.1%
Aug 04, 2020